Date:1/28/2011

HOLDERS OF CRUCELL ARE URGED TO READ THESE AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE OFFER. Copies of Johnson & Johnson’s filings with the SEC may be obtained at the SEC’s web site (www.sec.gov) or by directing a request to Johnson & Johnson at Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933, U.S.A. (Attention: Corporate Secretary’s Office). The Offer Document is available free of charge on the website of Crucell at www.crucell.com. Hard copies of the Offer Document will also be available at the offices of Crucell at Archimedesweg 4-6, 2333 CN Leiden, the Netherlands; at the offices of the Dutch Settlement Agent, ING Bank N.V., Bijlmerdreef 888 1102 MG Amsterdam, the Netherlands (Attention: Sjoukje Hollander/Remko Los), telephone: + 31 20 563 6546 / + 31 20 563 6619, email: iss.pas@ing.nl); and at the offices of the U.S. Settlement Agent, Computershare Trust Company, N.A., 250 Royall Street, Canton, MA 02021.

About CrucellCrucell N.V. (NYSE Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) is a global biopharmaceutical company focused on research development, production and marketing of vaccines, proteins and antibodies that prevent and/or treat infectious diseases. In 2009 alone, Crucell distributed more than 115 million vaccine doses in more than 100 countries around the world, with the vast majority of doses (97%) going to developing countries. Crucell is one of the major suppliers of vaccines to UNICEF and the developing world. Crucell was the first manufacturer to launch a fully-liquid pentavalent vaccine. Called Quinvaxem®, this innovative combination vaccine protects against five important childhood diseases. Over 180 million dos
'/>"/>

SOURCE Johnson & Johnson Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer
2. Johnson & Johnson Reports 2010 Fourth-Quarter and Full-Year Results
3. Johnson & Johnson Provides Update on McNeil Consumer Healthcare Remediation; Announces Completion of Internal Assessment Phase of Comprehensive Action Plan
4. Reportlinker Adds Johnson & Johnson: PharmaVitae Profile
5. Boston Scientific Announces Election of Dr. Kristina M. Johnson to its Board of Directors
6. Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee
7. Johnson & Johnson and Crucell Provide Progress Update on Preparations for Public Offer
8. Johnson & Johnson to Host Analyst Meeting to Discuss Third-Quarter Financial Results and Review Pharmaceutical Business
9. Two-Time Super Bowl Champion Coach & Sports Broadcaster Jimmy Johnson Laughs About His Notoriety in New ExtenZe Spots from Inter/Media Advertising
10. Surveyed European Oncologists Assign Greater Patient Share to Johnson & Johnsons Abiraterone Compared With Other Emerging Therapies in Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
11. Laureate Pharma Appoints Steven R. Johnson as Vice President, Business Development